Overview

Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant

Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether high dose IVIG and B cell depleting agents can be used effectively in highly sensitized wait-listed patients.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Roche Pharma AG
Treatments:
Immunoglobulins, Intravenous
Rituximab